Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, NEOGENOMICS, INC. reported revenue of $727M, up 10.1% year over year. Operating margin was -15.9% and net margin -14.9%, on a free-cash-flow margin of -3.0% with capital expenditure at 3.7% of revenue. Every figure is computed directly from NEO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $727M | -15.9% | -14.9% |
| FY2024 | $661M | -13.9% | -11.9% |
| FY2023 | $592M | -18.2% | -14.9% |
| FY2022 | $510M | -30.9% | -28.3% |
| FY2021 | $484M | -24.5% | -1.7% |
How does NEO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AACG · ABSI · ACCS · ACHC · ACM · ADUS
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.